Navidea Biopharma (NAVB) Tops Q4 EPS by 2c

Navidea Biopharma (NYSE: NAVB) reported Q4 EPS of ($0.02), $0.02 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $4.29 million versus the consensus estimate of $4.06 million.

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Bernstein SocGen Reiterates Outperform Rating on Fervo Energy (FRVO)